知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

117 条记录 (耗时 0.049 秒)

    Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
    2.
    发明授权
    Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts 有权

    公开(公告)号：US10918635B2

    公开(公告)日：2021-02-16

    申请号：US16364023

    申请日：2019-03-25

    申请人： Medicis Pharmaceutical Corporation

    发明人： Michael T. Nordsiek ,  Jefferson J. Gregory

    IPC分类号： A61K9/00 ,  A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/12 ,  A61K31/4745

    摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

    Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
    5.
    发明授权
    Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts 有权
    较低的剂量强度咪喹莫特配方和用于治疗生殖器和肛周疣的短剂量方案

    公开(公告)号：US09078889B2

    公开(公告)日：2015-07-14

    申请号：US14091965

    申请日：2013-11-27

    申请人： Medicis Pharmaceutical Corporation

    发明人： Michael T. Nordsiek ,  Jefferson J. Gregory

    IPC分类号： A01N43/42 ,  A61K31/44 ,  A61K31/4745

    CPC分类号： A61K31/4745 ,  A61K9/0014 ,  A61K9/06 ,  A61K31/44 ,  A61K47/10 ,  A61K47/12

    摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

    摘要翻译： 用于局部或透皮递送1异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基丙基）-1H-咪唑并[4,5-c]喹啉-2-酮的药物制剂和方法， 4-胺，即咪喹莫特，以现在由美国食品和药物管理局（FDA）批准的5％咪喹莫特乳膏市售的治疗时间短于治疗的生殖器/肛周疣， 被公开和描述。 更具体地说，低剂量强度的咪喹莫特制剂，以递送有效剂量的咪喹莫特，用于治疗生殖器/肛周疣，具有可接受的安全性和对于患者使用而言比目前由美国食品和药物当前批准的给药方案更短和更方便的给药方案 还公开和描述了用于治疗生殖器/肛周疣的Aldara 5％咪喹莫特乳膏的给药（“FDA”）。

    Therapeutic pyrazolyl thienopyridines
    7.
    发明授权
    Therapeutic pyrazolyl thienopyridines 有权
    治疗性吡唑并噻吩并吡啶类

    公开(公告)号：US08455512B2

    公开(公告)日：2013-06-04

    申请号：US13112520

    申请日：2011-05-20

    申请人： Stephen D. Barrett ,  James B. Kramer ,  Mark L. Boys ,  Huifen Chen

    发明人： Stephen D. Barrett ,  James B. Kramer ,  Mark L. Boys ,  Huifen Chen

    IPC分类号： A61K31/4365 ,  C07D495/04

    CPC分类号： C07D495/04 ,  A61K9/0014 ,  A61K31/4365

    摘要： The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

    摘要翻译： 本发明提供式I化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，R 6和R 7具有在本说明书中定义的任何值及其药学上可接受的盐， 可用作治疗TGFbeta介导的病症（包括癌症和纤维化疾病）的治疗剂。 还提供了包含一种或多种式I化合物的药物组合物。

    Method of treating actinic keratosis
    8.
    发明授权
    Method of treating actinic keratosis 有权
    治疗光化性角化病的方法

    公开(公告)号：US08354424B2

    公开(公告)日：2013-01-15

    申请号：US11886204

    申请日：2006-03-14

    申请人： James H. Lee ,  Terrance L. Fox

    发明人： James H. Lee ,  Terrance L. Fox

    IPC分类号： A61K31/44 ,  A61K31/4965

    CPC分类号： A61K31/4745 ,  A61K9/0014 ,  A61K9/06

    摘要： A method of treating actinic keratosis including applying topically to an actinic keratosis lesion twice per week for a duration of 8 weeks a formulation comprising 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine.

    摘要翻译： 一种治疗光化性角化病的方法，包括每周两次局部应用于光化性角化病病变，持续8周，包含2-甲基-1-（2-甲基丙基）-1H-咪唑并[4,5-c] [1 ，5]萘啶-4-胺。

    Mid-face aesthetic scale and related methods
    10.
    发明申请
    Mid-face aesthetic scale and related methods 审中-公开
    中期美学规模及相关方法

    公开(公告)号：US20120046576A1

    公开(公告)日：2012-02-23

    申请号：US13199113

    申请日：2011-08-19

    申请人： Xiaoming Lin ,  David Morgan ,  Ira Lawrence ,  Mitch Wortzman

    发明人： Xiaoming Lin ,  David Morgan ,  Ira Lawrence ,  Mitch Wortzman

    IPC分类号： A61B5/103

    CPC分类号： A61B5/442 ,  A45D2044/007 ,  A61B2576/02

    摘要： This disclosure relates to mid-face aesthetic scales and related methods for evaluating fullness in a mid-face area of a human patient's face. In exemplary embodiments, the mid-face area is defined as medial to the maxillary prominence, lateral to the medial canthus, inferior to the maxillary prominence, superior to the plane of nasal alae, and lateral to the nose. An exemplary method for evaluating fullness in a mid-face area of a human patient's face comprises visually comparing a plurality of views of the patient's mid-face against a mid-face scale, and assigning a grade from the scale to the patient's mid-face based on the visual comparison.

    摘要翻译： 本公开涉及用于评估人类患者面部的中间面积中的丰满度的中间面美学量表和相关方法。 在示例性实施例中，中间面积被定义为上颌突出的内侧，侧向于内侧凹陷，低于上颌突起，优于鼻颊平面，并且在鼻侧。 用于评估人类患者面部的中间面积中的丰满度的示例性方法包括将患者中间面的多个视图与中等面积比例进行视觉比较，以及将比例的等级分配给患者的中间面 基于视觉比较。